NF1 Treatment News: FDA Expands Selumetinib (KOSELUGO) Approval to Adults
NF Midwest is excited to share important news for our community, news that brings real hope to people living with…
Read More
Check out past blogs and news!
NF Midwest is excited to share important news for our community, news that brings real hope to people living with…
Read More
Researchers supported by NTAP have announced an exciting breakthrough in gene therapy for NF1. For the first time, scientists have…
Read More
When my son, Benjamin, came home from Camp NF this summer, he couldn’t stop talking about everything he had learned…
Read More
Did you know that November is National Epilepsy Awareness Month? According to the Epilepsy Foundation, individuals with NF1 are at…
Read More
Are you and your HCP often in agreement with your treatment plan for neurofibromatosis type 1 (NF1) or neurofibromatosis type…
Read More
Our 2025 iNFo Fair brought our NF community together with a powerful theme: Be Proactive, Be Informed, Be Heard. The…
Read More
🎁 Get ready for a little holiday windfall! On Wednesday, November 26th—just before Thanksgiving, Black Friday, and Cyber Monday—one lucky…
Read More
Gina Friesl, Patient Education Manager from Alexion Pharmaceuticals, will share information about Navigating Stress and Cultivating Wellness. Objectives: This is a…
Read More
They gave 10 AMAZING YEARS to the cause and raised a lot of funds. Thank you to the Oswald family…
Read More
Joe Booe, Patient Education Manager from Alexion Pharmaceuticals, will share information about transitioning to adult care. Objectives: This is a virtual…
Read More
© 2025 Neurofibromatosis Midwest - non profit 501(c)(t3). Site Map - Privacy Policy
The resources on this site should not be used as a substitute for professional medical care or advice on Neurofibromatosis. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional.
.png)
